SATELLOS BIOSCIENCE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.47 CAD | +2.17% |
|
+17.50% | +9.30% |
| 27/03 | Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 27/03 | Satellos Bioscience Announces FY 2023 Results | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 6.782 | 36.58 | 38.8 | - | - |
| Enterprise Value (EV) 1 | 6.782 | 36.58 | 38.8 | 38.8 | 38.8 |
| P/E ratio | - | - | -2.47 x | -2.35 x | -2.61 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 41,798 | 1,12,792 | 1,12,792 | - | - |
| Reference price 2 | 0.2200 | 0.4300 | 0.4700 | 0.4700 | 0.4700 |
| Announcement Date | 30/03/23 | 27/03/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -6.268 | -11.38 | -15.7 | -11.9 | -19.76 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -8.363 | -11.69 | -15.7 | -11.85 | -19.76 |
| Net income 1 | -8.368 | -11.69 | -15.7 | -11.85 | -19.76 |
| Net margin | - | - | - | - | - |
| EPS 2 | - | - | -0.1900 | -0.2000 | -0.1800 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 30/03/23 | 27/03/24 | - | - | - |
1USD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -1.419 | -1.593 | -1.229 | -3.209 | -3.268 | -4.598 | -4.038 | -3.849 | -3.887 | -3.926 | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -1.418 | -3.744 | -1.225 | -3.026 | -2.602 | -4.809 | -4.038 | -3.849 | -3.887 | -3.926 | - |
| Net income 1 | -1.719 | -1.418 | -3.748 | -1.225 | -3.026 | -2.602 | -4.809 | -4.038 | -3.849 | -3.887 | -3.926 | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | - | - | - | - | - | - | -0.0500 | -0.0500 | -0.0500 | -0.0500 | -0.0500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 29/08/22 | 23/11/22 | 30/03/23 | 30/05/23 | 28/08/23 | 22/11/23 | 27/03/24 | - | - | - | - | - |
1USD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 30/03/23 | 27/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.47
CAD
Average target price
1.2
CAD
Spread / Average Target
+155.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.30% | 38.8M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- MSCL Stock
- Financials Satellos Bioscience Inc.
